

Description of Supplemental Data for:

Vascular endothelial receptor tyrosine phosphatase: Identification of novel substrates related to junctions and a ternary complex with EphB4 and Tie-2

Hannes C. A. Drexler^{‡1,2}, Matthias Vockel^{¶#1}, Christian Polaschegg^{¶1}, Maike Frye[¶], Kevin Peters*, Dietmar Vestweber^{¶2}

From the [¶]Department of Vascular Biology, [‡]Bioanalytical Mass Spectrometry, Max Planck Institute for Molecular Biomedicine, Röntgenstr. 20, 48149 Münster, Germany; *Aerpio Pharmaceuticals, Cincinnati, OH 45242, USA; [#]Institute of Human Genetics, University Hospital Münster, 48149 Münster, Germany

- **Table S1:** List of all quantified protein(group)s obtained from the label-free inhibitor experiment (+/- AKB-9778; immunoprecipitation with 4G10 anti-phosphotyrosine antibody). Proteins had to be identified by at least 2 different peptides, 1 of which being unique for the proteingroup (S-1). List of all non-redundant peptides identified in this experiment (S-2)
- **Table S2:** List of all sites, identified in the 4G10 anti-phosphotyrosine – mediated immunoprecipitation experiment as being phosphorylated on S, T or Y residues (S-3). List of all class-I p(STY)-sites (localization probability > 0.75; S-4); List of all class-I pY-Sites (S-5); List of all Class-I pY-Sites, detected exclusively in AKB-9778-treated samples (S-6)
- **Table S3:** All protein(group)s identified and quantified with at least 2 peptides (1 unique) in the SILAC substrate trapping approach (S-7); List of all non-redundant peptides identified in this experiment (S-8)

- **Fig S1:** Venn diagram demonstrating the overlap of VE-PTP target proteins from the substrate trapping approach, the pY-peptide pulldown subsequent to treatment with the VE-PTP inhibitor AKB-9778 and those proteins that were identified in a global phosphoproteomics enrichment experiment upon exposure to AKB-9778.